• China has taken steps to regulate the Bitcoin mining and trading, fueling increased interest in overseas providers of crypto mining services
• ISWH has partnered with Bit5ive to innovate infrastructure needed to run innovative crypto mining projects
• Company has fundamental belief in long-term future viability of cryptocurrency systems as legitimate platforms for global commerce

The world of Bitcoin took a hit earlier this year, falling almost 50% after China increased its efforts to regulate the space (https://ibn.fm/twCpI). Concerns about the cryptocurrencies are nothing new, and ISW Holdings (OTC: ISWH), a global brand management holdings company, has established itself in the cryptocurrency mining space and is committed to providing compliant, efficient and profitable crypto mining projects. “Beijing stepped up its efforts to crack down on Bitcoin mining and trading, sending the digital currency tumbling,” a recent article reported. “Bitcoin took a hammering after the latest Chinese move and is now down nearly 50% from its all-time high. It shed as much as 17% on Sunday, before paring some losses and was last trading steady in Asia.” The article noted that a Chinese State Council committee announced the efforts May 21, the first time the council has targeted virtual currency mining, a big business in China that accounts for as much as 70% of the world’s crypto supply. “Investor protection and prevention of money laundering are particular concerns of governments and financial regulators who are grappling with whether and how they should regulate the cryptocurrency industry,” noted the article, which also observed that Chinese miners were contacting overseas service providers to pave way for exports of mining rigs in the future.” ISW Holdings has partnered with Bit5ive, a global leader in cryptocurrency mining, to innovate the infrastructure needed to run profitable and efficient crypto mining projects. As a result, the company developed a revolutionary Pod5 Cryptocurrency Mining Pod, which has been in full operation at the Bit5ive renewable energy cryptocurrency mining facility in Pennsylvania since February (https://ibn.fm/osx8u). “We are very excited to finally be ready to launch full mining operations at a time when margins are at historic levels following further strength in the value of cryptocurrency assets,” said ISW Holdings president and chair Alonzo Pierce when announcing the news. “But make no mistake about it: we are doing this because we have a fundamental belief in the long-term future viability of cryptocurrency systems as stores of value and legitimate platforms for global commerce. We started diversifying our cash into Bitcoin nearly two years ago. And we partnered with Bit5ive early last year and began the design for our Pod5 unit when Bitcoin was still under $10,000 per coin.” Designed in partnership with Bit5ive and geared primarily for the cryptocurrency mining industry, the Pod5 Datacenter offers next-generation, dynamic, self-management functionality, plug-and-play operation, virtually nonexistent maintenance needs, and an industry best-in-class 1.06 Power Usage Effectiveness score. The Pod5 is a strong example of ISWH’s commitment to and position in the crypto space. ISW Holdings is a diversified portfolio company comprised of essential business lines that serve consumer product demands. The company’s expertise lies in strategic brand development and early growth facilitation, as well as brand identity through its proprietary procurement process. Together with its partners, ISWH seeks to provide a structure that meets large scalability demands and anticipated marketplace needs. The company meets those needs through a variety of strategic innovative processes. ISW Holdings is creating and managing brands across a spectrum of disruptive industries. It maneuvers its proprietary companies through critical stages of market development, which includes conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency. For more information, visit the company’s website at www.ISWHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

• Infobird successfully launches Intelligent Quality Inspection SaaS for a leading fintech company
• Infobird’s Intelligent Quality Inspection system will enhance the fintech company’s management and customer service capabilities
• Infobird researched and analyzed the customer service business scenarios of its client, and built a flexible multi-dimensional quality inspection model

Infobird (NASDAQ: IFBD) Software is a SaaS (Software-as-a-Service) company, providing AI-enabled end-to-end (“B2B”) customer engagement solutions in China, mainly for the finance segment. A premier provider of customer engagement software-as-a-service (“SaaS”) solutions in China, the company announced the successful implementation of its Intelligent Quality Inspection SaaS with one of the leading Fintech companies in China. With the launch of Infobird’s Intelligent Quality Inspection SaaS, Fintech has initiated intelligent management and operations for its client’s customer service platform, paving way for a further upgrade of its customer service (https://ibn.fm/auARB). The Fintech company introduced Infobird’s Intelligent Quality Inspection system to enhance its management and customer service capabilities. The Inforbird client has greatly advanced its customer service quality inspection from manual inspection by random sampling to automatic inspection resulting in a multitude of benefits in the form of a 100% quality inspection coverage rate with improved managerial efficiency. The employment of the SaaS System led to cutting down of services of quality inspectors, resulting in cost curtailment. The quality inspection efficiency also increased by more than 100 times. Inforbird has designed and developed Intelligent Quality Inspection SaaS for the Fintech client company. It researched and analyzed the customer service business scenarios of its client, and built a flexible multi-dimensional quality inspection model. Quality inspection personnel can now concentrate on more critical areas of work, such as conducting customer service training and management work and achieve greater productivity. Some performance-enhancing features of Infobird’s Intelligent Quality Inspection system are:

• Extensive inspection and targeted enhancement of services
• 100% automatic and efficient, enhancing workforce efficiency
• Multi-dimensional reports comprehensively improve management efficiency

In 2020, the SaaS industry in China was valued at $3.3 billion, an increase of 43.5% over 2019. The emergence of the pandemic acted as a catalyst to remote work opportunities has also accelerated the increased acceptance of cloud business services. A provider of customer engagement software-as-a-service (“SaaS”) solutions in China, Infobird is leveraging this growth opportunity to offer automated and smart capabilities to maximize value for its clients. For more information, visit the company’s website at www.Infobird.com/en/index.html. NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• Avricore Health is an innovator in pharmacy based point-of-care diagnostics
• The company introduced its flagship technology platform in an Ontario Shoppers Drug Mart pharmacy earlier this month as the lead-out to a 12-store rollout throughout the province
• Avricore’s trademarked HealthTab network is making diagnostic tools for diabetes and cardiovascular disease management accessible to patients and the Shoppers Drug Mart agreement provides community locations as well as pharmacist support
• The trial rollout showed successful use by over 90 patients during a week-and-a-half period with seamless pharmacist personnel assistance for more than 600 test results
• Financing programs in January and February helped Avricore retire $1 million in debt with enough left over to help fund the company’s platform expansion

Pharmacy diagnostics solutions developer Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is celebrating the successful test rollout of its flagship platform for assessing cardiovascular disease and diabetes in Shoppers Drug Mart, Canada’s largest pharmacy network. Avricore’s trademarked HealthTab network technology platform using Abbott Afinion 2(TM) analyzers for assessing cardiovascular and diabetes markers will be rolled out for point-of-care service in 12 Shoppers Drug Mart locations under an agreement announced June 3 (https://ibn.fm/I4Lg6). Between July 5 and July 18, Avricore conducted an initial trial period of the health management data platform in an Ontario, Canada Shoppers Drug Mart store and found that more than 90 patients were tested and over 600 results were reported during the week and a half period. “This is really profound because having access to lab-accurate results at our fingertips means we can better help family physicians by conducting regular follow up using advanced diagnostics with our diabetic and cardiovascular patients more effectively,” pharmacist and associate owner Mohamed Adel Elsabakhawi stated (https://ibn.fm/QId4K). The purpose of the rollout is to help patients, beginning in Ontario, to live life well using effective tools and services to successfully manage their overall health with the support of a trusted pharmacist. The world’s leading health organizations and experts have made accessibility to self-help management technology an increasing priority, and walk-in community pharmacies are ideal hub locations for patients to seek those services for diagnosing infections and preventing or treating chronic medical conditions. Last year, the global point-of-care diagnostics market was evaluated at nearly $34.5 billion in revenue, according to Fortune Business Insights, and was expected to grow at a compound annual growth rate (“CAGR”) of 9.4 percent through 2028 to reach $81.37 billion (https://ibn.fm/juCx0). Avricore secured two rounds of financing in early 2021 — one that closed $1.5 million and a second that brought in $1.54 million, with warrants for more than $1 million also exercised — which allowed the company to repay a secured debt of $1 million with sufficient extra cash to advance expansion plans (https://ibn.fm/SfMO3). The 12 Ontario Shoppers Drug Mart pharmacies have now all received their HealthTab systems and are in the process of bringing them online as part of that expanding effort to help patients manage their care. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• HempFusion’s acquisition of Sagely Naturals opens the company to over 14,000 additional retail stores
• It marks a massive milestone following the $17 million TSX IPO in January 2020
• HempFusion looks to more than triple its 2020 revenue as this is part of the company’s expansion plan for 2021 and beyond
• The move builds on HempFusion’s five-channel strategy while playing into Sagely Naturals’ opportunities and strengths

2021 is proving to be a good year for HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO). In January, it completed its $17 million IPO to start trading on the Toronto Stock Exchange (“TSX”) (https://ibn.fm/8hTot). Fast forward to July; the company acquired Sagely Naturals in its most significant move yet as it works on a five-channel expansion strategy to conquer various markets, including the Middle East, China, India, Mexico, Europe, and South Korea (https://ibn.fm/cMnAc). HempFusion’s acquisition of Sagely Naturals opens it to an additional 14,000 stores along with the latter’s retail distribution footprint. It also opens the company to product efficiencies across the topicals line while diversifying its overall product line that features its proprietary formulations. Before Sagely Naturals’ acquisition, HempFusion offered 48 different products under a handful of brands, including Biome Research, HF Labs, Probulin Probiotics, and HempFusion (https://ibn.fm/QSoSq). They were sold in at least 4,000 retail locations in all 50 states within the United States through five main channels: e-commerce, natural health retailers, convenience stores, doctors/practitioners, and big-box/food and drug mass. With Sagely Naturals in the picture, HempFusion now has access to the company’s robust distribution systems and infrastructure. Additionally, it has the opportunity to grow further its product line and, most importantly, leverage Sagely Naturals’ industry-leading marketing, advanced customer/channel relationships, and its proven innovation. Also, with Sagely Naturals’ acquisition, HempFusion looks to more than triple its 2020 revenue with its expansion plan for 2021 and beyond. “We are incredibly excited to complete the acquisition of Sagely Naturals which provides HempFusion with a significant increase in revenue and immediate distribution to up to an additional 14,000 retail points nationally,” noted John Mitchell, the Chief Executive Officer (“CEO”) of HempFusion. “Integration has been underway over the past several weeks, and we look forward to driving shareholder value through continued growth in 2021 and 2022 both domestically and internationally with our expanding family of brands,” he added. So far, HempFusion has successfully managed to win over big retailers with its hemp CBD products. Most notably, the company’s presence on Amazon has played a vital role in its success, brand recognition, and overall brand perception. With the Sagely Naturals’ acquisition, HempFusion plans on taking it a step further while also paying close attention to regulatory compliance procedures that will allow it to expand to other key markets across the world. HempFusion’s focus over the past two and a half years has been on building a solid catalog for its products, ensuring all regulatory compliance guidelines are met and expanding its retail store footprint. With the CBD sector projected to get to $16.8 billion by 2025, the Sagely Naturals’ acquisition could not have come at a better time. HempFusion is a leading health and wellness CBD company that utilizes the power of whole-food hemp nutrition. The company is committed to consistently meeting and exceeding the high standards required by retailers and consumers by prioritizing the quality and consistency of its products. The company is U.S. Hemp Authority Certified and even serves as a board member of the U.S. Hemp Roundtable, a coalition of leading companies committed to advancing safe hemp and CBD products. Sagely Naturals’ acquisition marks a key milestone for HempFusion in its 2021 expansion plan. It builds on the company’s progress so far while laying down a solid foundation for its future expansion in terms of its product line and market reach. For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to CBDHF are available in the company’s newsroom at https://ibn.fm/CBDHF

• Ideanomics plans to release its 2021 second-quarter financial results on Monday, August 16, 2021
• The press release is scheduled at 4 pm ET and will be followed by a conference call at 4:30 pm ET
• The call will have the company’s senior management sharing their thoughts on the company’s performance
• It will also have a question-and-answer session for the audience

Ideanomics (NASDAQ: IDEX) will release its 2021 second-quarter financial results on Monday, August 16, 2021. The press release will be issued at 4 pm ET and will be accompanied by a conference call at 4:30 pm ET (https://ibn.fm/uDgF9). The event will feature Ideanomics’ senior management, where they will share their thoughts on its performance so far in the 2021 fiscal year. The session will also provide engagement with the audience, where attendees will get the chance to ask the management questions and have the latter respond to them (https://ibn.fm/x7xbE). Ideanomics is a company that is playing a pivotal role in the adoption of commercial electric vehicles. Its business also involves offering support for next-generation financial services and fintech products. The company is more known known, specifically for its electric vehicle division, Ideanomics Mobility. Ideanomics also has a fintech side to their business under the Ideanomics Capital division. Should you be interested in attending the virtual conference, there are two options to choose from, namely:

1. Webcast Link: https://ibn.fm/30z5X
2. Dial-in Number: 877-407-3107 or 201-493-6796 (Toll-Free for the United States) and Canada

To view the replay of the virtual conference and read the earnings material, check out the company’s investor relations website https://investors.ideanomics.com. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• President Biden signed executive order directing U.S. Department of Health and Human Services to consider issuing proposed rules to allow hearing aids sales over the counter
• INND positioned to capture market share through online DTC sales of Bluetooth-powered self-adjusting rechargeable hearing aids
• Company recently launched massive six-month campaign to run a minimum of 660 commercials across major networks including Fox News, Bloomberg, Fox Business Network, CNN, CNBC, Newsmax TV, MSNBC

With the aim of promoting “greater competition in the American economy”, President Biden signed a sweeping executive order in early July that directs the U.S. Department of Health and Human Services “to consider issuing proposed rules within 120 days for allowing hearing aids to be sold over the counter” (https://ibn.fm/oG58N). In anticipation of the increased demand for over the counter (“OTC”) hearing aids, InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer (“DTC”) hearing technology space, recently launched a six-month national “Media Blitz” campaign aimed at an estimated 48 million Americans currently suffering from hearing loss (https://ibn.fm/kdCpp). Depending on the level of technology, hearing aids can cost up to $6,000 for each device, making them prohibitively expensive for millions of hearing-impaired Americans (https://ibn.fm/71geF). “A major driver of the expense is that consumers must get them from a doctor or a specialist, even though experts agree that medical evaluation is not necessary,” reads the executive order summary (https://ibn.fm/vBRAZ). “Rather, this requirement serves only as red tape and a barrier to more companies selling hearing aids. The four largest hearing aid manufacturers now control 84% of the market”. InnerScope Hearing Technologies is favorably positioned to capture the anticipated increase in consumer demand through direct-to-consumer sales of its Bluetooth-powered self-adjusting rechargeable hearing aids at its dedicated online store. The Company recently launched a “Media Blitz” campaign in partnership with New to The Street TV to increase public awareness about hearing loss and drive sales to its website. The six-month campaign guarantees a minimum of 660 commercials over the period, including 156 digital billboards running three times per hour throughout lower Manhattan in New York City. Along with broadcasting televised commercials on Fox News, Bloomberg, Fox Business Network, CNN, CNBC, Newsmax TV, and MSNBC, the company plans to use the content – owned by InnerScope Hearing Technologies as part of the agreement – on its website and social media platforms. “The launch of our Hearing Loss Media Blitz Campaign could not have come at a better time, especially after last week’s executive order from President Biden and his remarks on making hearing aids more affordable and able to be sold over the counter in pharmacies without any medical evaluation,” said InnerScope Hearing Technology CEO Matthew Moore. “InnerScope’s hearing aids work with any smartphone, require no medical evaluation or professional help, and deliver the same personalized hearing quality and satisfaction as hearing aids sold by hearing care professionals.” InnerScope Hearing Technologies is dedicated to improving the quality of life for over 70 million North Americans and 1.5 billion people worldwide that suffer from hearing impairment and hearing-related issues. The company produces, distributes and markets direct-to-consumer FDA-registered Bluetooth app-controlled hearing aids, Bluetooth app-controlled personal sound amplifier products and hearing-related treatment therapies that include doctor-formulated dietary hearing and tinnitus supplements and other health-related products. For more information, visit the company’s website at www.INND.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

Microdose Psychedelic Insights (“Microdose”) are set to host their virtual Pyschedelic Capital: July 2021 conference on July 29, 2021. The event is set to play host to a number of companies, drawn from across the psychedelics industry, including, but not limited to, the functional mushrooms and phytopharmaceutical sectors. Microdose Psychedelic Insights, a cutting-edge media company focused around promoting content, financial analysis, and engaging events focused around the psychedelics industry, have gained renown for their unique vision towards shifting the global perception around psychedelic medicine through a series of innovative events. Part of an investor conference series diving deep into psychedelic medicine investment, Microdose’s Psychedelic Capital conference seeks to introduce investors and attendees to a curated group of CEOs, capital advisors and investment luminaries from around the world. This year’s July conference will be inaugurated by an introductory talk, delivered by Patrick Moher, CEO of Microdose Psychedelic Insights; and Richard Skaife, Founding Partner at The Conscious Fund, an early-stage venture capital investor within the plant powered medicine sector. The conference will subsequently play host to a number of corporate presentations from companies focused around medicinal mushroom-based products, the cultivation and processing of pharmaceutical and medicinal cannabis, psychedelic-based disease modifying therapies, among various others. In addition, the event will also feature an exciting roundtable symposium focused around the latest ongoing developments and breakthroughs within the global psychedelics industry. Additional information about the Psychedelic Capital: July 2021 conference, as well as details for registration, can be found on the Psychedelic Capital conference website at https://microdose.buzz/shop/events/psychedelic-capital/psychedelic-capital-jul-2021/ About Microdose Psychedelic Insights: Microdose Psychedelic Insights is your guide to the psychedelic medicine industry. With a vision to shift the world’s perception of psychedelic medicine, we distribute and create the most compelling content, financial analysis, engaging events, and groundbreaking education to drive the psychedelics industry to the forefront of modern medicine. About Psychedelic Capital: This online event programming is dedicated to providing investment grade information for the nascent psychedelic sector and presents a curated group of CEOs, financial experts, thought leaders and investment luminaries from around the globe. Presentations are 30 minutes in length, with 10 minutes always allocated to a one-on-one Q&A session with the audience. Psychedelic Capital features the top companies, latest IPOs, newest opportunities and deepest insights into the emerging psychedelic space. Contact: Microdose Psychedelic Insights kristina@microdose.buzz Media Contact:  InvestorBrandNetwork (IBN) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

• StorEn’s batteries deliver superior performances at a lower cost
• Company’s exclusive vanadium flow battery technology is based on a rechargeable flow battery
• With its innovative vanadium flow battery tech as a backdrop, the company is in the process of a RegA offering with four different investment tiers

From the first all-vanadium flow battery created almost four decades ago, StorEn Technologies has developed a revolutionary vanadium flow battery technology that has potential to revolutionize the energy-storage space. StorEn’s batteries deliver superior performances at a lower cost; they also fulfill growing market demand for more efficient and cost-effective energy storage (https://ibn.fm/Cw1Z4). StorEn’s exclusive vanadium flow battery technology is based on a rechargeable flow battery that stores energy using the ability of vanadium to exist in solution in four different oxidation states. The company uses this unique property of vanadium to produce batteries with just one electroactive element instead of two, eliminating the possibility of metal cross-contamination. The company’s current design was patented in 1986 by the University of New South Wales in Australia, where the first known commercial example of the all-vanadium flow battery was created by Dr. Maria Skyllas-Kazacos and her team. StorEn’s technology has also been influenced by information and research conducted and reported by individuals such as P.A. Pissoort in the 1930s and NASA researchers A. Pelligri and P.M. Spaziante in the 1970s. StorEn’s batteries have proven ability to discharge fully at 100% without decaying and losing capacity, unlike lithium batteries. To consumers, this means that 100% of the battery’s initial capacity will be available throughout the lifetime of the battery, which is in excess of 25 years. Thus no oversizing is needed and no additional costs will be incurred to compensate from the capacity lost over time. Maintenance on StorEn batteries is also game changing. Because the battery management system alerts the user when service is needed, consumers no longer need to schedule regular maintenance. Finally, because vanadium flow batteries are just seeing development begin, improvements are certain to come. Examples of anticipated advancement could include new components such as new membranes. In addition, as the technology becomes more widespread, cost reductions and economies of scale from higher performance as well as volume manufacturing of batteries and components are likely. With its innovative vanadium flow battery tech as a backdrop, the company is in the process of a RegA offering with four different investment tiers; each tier offers a different discount and reward. (Click here for more information.) With a proprietary product that answers the call for long-lasting, 100% recyclable, safe and affordable energy storage, StorEn is in an ideal position to leverage its disruptive, patent-pending, all-vanadium flow battery technology in a growing market. Incubated at the Clean Energy Business Incubator Program (“CEBIP”) within Stony Brook University in New York, StorEn is building upon the strengths of vanadium flow batteries to revolutionize the world of residential and industrial energy storage. For more information, visit the company’s website at www.StorEn.tech. NOTE TO INVESTORS: The latest news and updates relating to StorEn Technologies are available in the company’s newsroom at https://ibn.fm/StorEn

• Lexaria Bioscience has completed a study conducted by Canada’s National Research Council for the use of its DehydraTECH IP with five drugs known to target the main protease associated with SARS-CoV-2 infection, including remdesivir
• The SARS-CoV-2 infection is the underlying force behind the COVID-19 pandemic that has killed millions of people during the past year and currently has begun trending toward a rising infection rate again
• DehydraTECH technology helps drugs gain better bioavailability through quick and effective introduction into patients’ bloodstreams using oral administration as opposed to injections
• The recent study results demonstrate that DehydraTECH-processed remdesivir, ebastine, bepridil, rupintrivir, and colchicine, did not create unwanted covalently-bonded new molecular entities (“NMEs”), or changes in chemical structure

Media outlets have been reporting a new rising trend in COVID-19 infections, signaling health policy concerns about the potential for significant new demands on the medical community and raising questions about the sociological implications in the United States shortly before the new school year opens (https://ibn.fm/bMAMO). Many people remain unvaccinated and for anyone who contracts any viral disease including common influenza, drug treatment options can be the difference between life and death. Pharmaceutical technology innovator Lexaria Bioscience (NASDAQ: LEXX) announced success in the latest developmental step that may help antiviral medicines used to treat COVID or HIV/AIDS reach the bloodstream more effectively than ever. Lexaria announced July 15 that its antiviral drug molecular characterization study performed by the National Research Council (“NRC”), Canada’s premier federally funded research organization, has successfully demonstrated that Lexaria’s trademarked DehydraTECH platform does not create a covalently bonded new molecular entity (“NME”) when used to process select antiviral drugs (https://ibn.fm/Z3fEV). The results confirmed that the drugs tested remained stable and did not undergo changes in chemical structure when processed with DehydraTECH.  This could preserve the ability of this drug delivery platform to qualify for accelerated regulatory filings with the Food and Drug Administration (“FDA”) in the United States plus regulators elsewhere in the world. DehydraTECH was tested in conjunction with market-available antiviral drugs remdesivir, ebastine, bepridil, rupintrivir and colchicine, which are being investigate for possible use against the SARS-CoV-2 virus. The virus’ aggressive spread has been the root cause of the pandemic that has sickened some 192 million people and killed more than 4 million of them worldwide during the past year (https://ibn.fm/AnH8V). The potential for more rapid market authorizations of DehydraTECH provides the potential for cost savings to the healthcare system to try to deliver antiviral drugs more effectively if it can be delivered via an oral capsule instead of by injection. “We are looking at repurposing some of these drugs, being able to take an antiviral drug that traditionally could only be administered, for example, by injection. We might be able to apply it in an oral form through a pill,” Lexaria CEO Chris Bunka told Investing News Network (https://ibn.fm/buyWB). Delivering the medications in the form of a pill instead of a shot could help governments or health insurance companies save billions of dollars in administration costs alone. In December, the company announced the current stage of R&D for drugs known to target the main protease associated with SARS-CoV-2 infection, using male Sprague-Dawley rats to quantify and compare total drug delivery into the rodent bloodstream to control formulations (https://ibn.fm/QyeoO). “We are excited to work with remdesivir, one of the world’s leading drugs currently in use for treatment of COVID-19, to learn whether DehydraTECH may also enhance drug delivery characteristics of NtRTI’s,” Bunka said at the time. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• American Cannabis Partners (“ACP”) is a Northern California-based organic cannabis cultivation company that has assimilated the strengths of Jamaica’s marijuana growing reputation to create a stable and distinctive brand
• The company primarily employs rigorously vetted Jamaicans experienced and knowledgeable in growing strains of product that recreate the Caribbean Island’s product for licensing and sales under ACP’s ZÜK brand
• The overall cannabis industry is growing rapidly in the United States, with an anticipated market valuation of $30 billion by 2025
• Ironically, it’s more difficult than ever to get Jamaica’s famed marijuana in the Caribbean because of pandemic-related factors plus a devastating hurricane and drought during the past year

California and Michigan are the new places for a Jamaican getaway — if your getaway plans include a little ganja. While 2021 has been a bit brutal for the Caribbean island nation’s famed but largely illegal marijuana market, sustainable Jamaican experience canna-business innovator American Cannabis Partners (“ACP”)  is replicating the growing, feeding, temperatures, harvesting, and curing processes of Jamaican techniques to create a product unlike any other grower’s in the United States. An important factor in all of this is ACP’s close personal and positive relationship with the nation and people of Jamaica; a deep awareness of needs and not just business numbers. American Cannabis Partners employs a staff that is 90 percent Jamaicans hand-picked through what the company describes as an extremely difficult vetting process requiring not only the correct U.S. immigration status but also at least 10 years of experience in Jamaican growing and processing, with knowledge of certain strains and their characteristics that help ACP to gain a definable advantage in the organically grown cannabis industry. ACP’s partners use proprietary soil as well as recreated Jamaican natural supplements and environments to produce a product with more yield, faster growth, higher THC levels and more pronounced terpenes than the industry standard. The company is based in Northern California’s Emerald Triangle and distributes its ZÜK brand proprietary strains to partner California distributors and its own Michigan retail location. About 80 percent of its product is supplied to licensees for manufacturing, distribution and retail. Jamaica has long been a destination for pot, reggae and Rastafarians but has officially maintained a “just say no” approach to the leafy green drug. Terpene tourists recognize that enforcement is spotty and that the country has made some small decriminalization efforts in recent years. But last year’s heavy hurricane season, followed by a scorching drought this year, along with COVID pandemic-induced increases in local consumption and declines in the number of marijuana farmers, have caused tens of thousands of dollars in losses and shortages of bud on the street (https://ibn.fm/xCahT). California and Michigan have state-legal marijuana industries for adult recreational use, providing a fertile field of opportunity for ACP’s profile of raw product in multiple forms at wholesale prices for both medical and recreational use. The overall cannabis industry is growing rapidly in the United States, spurred on by the rapid adoption of plant-tolerant legislation in varying degrees of expression throughout the states and the federal Farm Bill legislation that made hemp a deregulated agricultural product. The U.S. cannabis industry alone is expected to reach $30 billion in market value annually by 2025 (https://ibn.fm/XOzkX). All of which portends optimism for the future of ACP’s efforts. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP